What this study is
The overall purpose of this research is to determine whether new macromolecular measures optimized for whole brain (gray matter and white matter) magnetic resonance imaging (MRI), predict neuro-cognitive impairment in multiple sclerosis (MS) patients.
What's being tested
- MRI
Intervention · DIAGNOSTIC TEST
The MRI protocol will include conventional testing for MS lesion detection and functional MR imaging to localize associated neurocognitive domains in each subject.
- Neuropsychological Testing
Intervention · DIAGNOSTIC TEST
A comprehensive battery of neuropsychological tests will be administered to assess memory, new learning, spatial processing and higher executive function.
Study details
- Sponsor
- University of Wisconsin, Madison
- Conditions
- Multiple Sclerosis · MS
- Enrolling
- 75 people
- Starts
- 2021-11-19
- Est. completion
- 2027-04
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 60 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Clinically definite MS
- Adult age 18 to 60
You can't join if
- Contraindication to MRI
- Changes in MS therapy in the last 6 months
- Less than 6 weeks after relapse or corticosteroid use
- Currently taking medication that may affect cognition (e.g. donepezil, rivastigmine, adderall)
- History of significant alcohol or drug abuse
- Current or recent significant migraines
- Confounding neurological or cognitive disorders or deficits (stroke, Parkinson's disease, Alzheimer's disease, epilepsy)
- Sensory or physical impairments that might interfere significantly with cognitive testing
- History of developmental or learning disability or attention-deficit/hyperactivity disorder.
- History of alcohol/drug abuse
- History of migraines
- Developmental or learning disability/attention-deficit/hyperactivity disorder
- Currently pregnant/breastfeeding
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Wisconsin, Madison
Madison, Wisconsin, United States
Study team
Sponsor
University of Wisconsin, Madison
Study ID 2020-0310
Principal investigator
Alexey Samsonov, PhD
UW Madison
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.